IGF1R and neoplasm: Small molecules targeting IGF1R, including picropodophyllin (PPP) as well as the investigational drugs, BMS754807 and linsitinib, have been shown to increase the anti-tumor efficacy of chimeric antigen receptor (CAR) engineered T cells (100, 101).